Search Results

You are looking at 71 - 80 of 483 items for :

  • "paclitaxel" x
  • Refine by Access: All x
Clear All
Full access

Cervical Cancer, Version 2.2015

Wui-Jin Koh, Benjamin E. Greer, Nadeem R. Abu-Rustum, Sachin M. Apte, Susana M. Campos, Kathleen R. Cho, Christina Chu, David Cohn, Marta Ann Crispens, Oliver Dorigo, Patricia J. Eifel, Christine M. Fisher, Peter Frederick, David K. Gaffney, Ernest Han, Warner K. Huh, John R. Lurain III, David Mutch, Amanda Nickles Fader, Steven W. Remmenga, R. Kevin Reynolds, Nelson Teng, Todd Tillmanns, Fidel A. Valea, Catheryn M. Yashar, Nicole R. McMillian, and Jillian L. Scavone

single agents in the metastatic disease setting based on several randomized phase III trials. 18 , 19 Cisplatin is a standard backbone of combination chemotherapy regimens, and cisplatin-based chemotherapy regimens (eg, cisplatin/paclitaxel

Full access

Point: Intraperitoneal Chemotherapy in the Management of Ovarian Cancer

Maurie Markman

: 4265 – 4269 . 16 Francis P Rowinsky E Schneider J . Phase 1 feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: A Gynecologic Oncology Group pilot study . J Clin Oncol 1995 ; 13 : 2961 – 2967 . 17 Markman

Full access

Chemotherapy Hypersensitivity Reactions in Ovarian Cancer

Matthieu Picard, Ursula A. Matulonis, and Mariana Castells

doxorubicin (PLD) seems to significantly reduce the incidence of HSRs attributable to carboplatin compared with administering carboplatin as a single agent or in combination with paclitaxel. 31 , 32 The effect of PLD on reducing carboplatin-related infusion

Full access

Novel Agents for Metastatic Triple-Negative Breast Cancer: Finding the Positive in the Negative

Neelima Vidula, Leif W. Ellisen, and Aditya Bardia

III study compared veliparib with carboplatin and paclitaxel followed by maintenance veliparib versus chemotherapy in germline BRCA1/2 -mutant HER2-negative advanced breast cancer. 18 Median PFS improved from 12.6 to 14.5 months with the addition of

Full access

Updates in HER2-Positive and Triple-Negative Breast Cancers

Presented by: Melinda L. Telli and William J. Gradishar

1mic disease. 3 Treatment with weekly paclitaxel for 12 cycles plus trastuzumab for 1 year led to a 7-year OS rate of 95%, with only 4 of 406 patients experiencing distant recurrences. The subsequent ATEMPT trial evaluated the newer agent ado

Full access

PACIFIC: An Ocean of Hope in Patients With Stage III Unresectable Non–Small Cell Lung Cancer

Dipesh Uprety and David E. Marinier

used for concurrent CRT, including cisplatin/etoposide, carboplatin/paclitaxel, cisplatin/vinblastine, and, for nonsquamous pathology, carboplatin or cisplatin with pemetrexed. 7 The carboplatin/paclitaxel regimen is given weekly with radiation therapy

Full access

HSR21-060: Real-World Treatment Patterns After Trastuzumab-Based Regimen in Patients With HER2-Positive Metastatic Gastric Cancer in the United States

Feng Lin, Jinlin Song, Melissa Pavilack, Jipan Xie, Catherine Fernan, Ahmed Noman, and Winghan Jacqueline Kwong

patients who used TBR as 1L, 130 initiated 2L treatment and trastuzumab was used again as 2L in 72 patients. The most common regimens used in 2L post 1L TBR were paclitaxel + ramucirumab (15.4%), FOLFOX + trastuzumab (11.5%), and capecitabine + trastuzumab

Full access

CRE24-050: Microangiopathic Hemolytic Anemia as the Presenting Manifestation of Metastatic Breast Cancer

Nirmala Ghimirey, Phuong Uyen Vo, James Dibb, Jordan Hatch, and Sameer Mahesh

carcinoma: ER+/PR-/HER2-. The patient’s most recent mammography was two months prior to presentation and did not show evidence of malignancy, even in retrospective analysis. With the diagnosis of metastatic breast cancer, she was started on paclitaxel. After

Full access

Ovarian Cancer, Version 2.2013

Robert J. Morgan Jr, Ronald D. Alvarez, Deborah K. Armstrong, Robert A. Burger, Lee-may Chen, Larry Copeland, Marta Ann Crispens, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Lainie Martin, Ursula A. Matulonis, David M. O’Malley, Richard T. Penson, Matthew A. Powell, Steven W. Remmenga, Paul Sabbatini, Joseph T. Santoso, Julian C. Schink, Nelson Teng, Theresa L. Werner, Mary A. Dwyer, and Miranda Hughes

measuring less than 1 cm after debulking, survival was increased by 16 months after IP therapy using cisplatin/paclitaxel when compared with standard intravenous therapy (65.6 vs 49.7 months; P =.03). 15 Recent long-term follow-up data have confirmed this

Full access

NCCN Guidelines Insights: Cervical Cancer, Version 1.2020

Featured Updates to the NCCN Guidelines

Nadeem R. Abu-Rustum, Catheryn M. Yashar, Sarah Bean, Kristin Bradley, Susana M. Campos, Hye Sook Chon, Christina Chu, David Cohn, Marta Ann Crispens, Shari Damast, Christine M. Fisher, Peter Frederick, David K. Gaffney, Robert Giuntoli II, Ernest Han, Warner K. Huh, John R. Lurain III, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Amanda Nickles Fader, Steven W. Remmenga, R. Kevin Reynolds, Rachel Sisodia, Todd Tillmanns, Stefanie Ueda, Renata Urban, Emily Wyse, Nicole R. McMillian, and Angela D. Motter

doublet and triplet chemotherapy regimens (ie, cisplatin/paclitaxel, carboplatin/paclitaxel, topotecan/paclitaxel, and topotecan/paclitaxel/bevacizumab) were restratified according to the NCCN Categories of Preference. In addition, emerging data on a new